Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies

References

• Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):1–6. doi: 10.2215/CJN.11761116.
   PubMed Web of Science ®Google Scholar
• Tesar V, Hruskova Z. Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy. Front Immunol. 2021;12:593288. doi: 10.3389/fimmu.2021.593288.
   PubMed Web of Science ®Google Scholar
• Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int. 2019;95(2):429–438. doi: 10.1016/j.kint.2018.10.021.
   PubMed Web of Science ®Google Scholar
• Qin HZ, Zhang MC, Le WB, et al. Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. J Am Soc Nephrol. 2016;27(10):3195–3203. doi: 10.1681/ASN.2015080953.
   PubMed Web of Science ®Google Scholar
• Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689–690. doi: 10.1056/NEJMc1011678.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797–804. doi: 10.1038/ki.2012.209.
   PubMed Web of Science ®Google Scholar
• Svobodova B, Honsova E, Ronco P, et al. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839–1844. doi: 10.1093/ndt/gfs439.
   PubMed Web of Science ®Google Scholar
• Bobart SA, Han H, Tehranian S, et al. Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study. Clin J Am Soc Nephrol. 2021;16(12):1833–1839. doi: 10.2215/CJN.05480421.
   PubMed Web of Science ®Google Scholar
• KDIGO. Chapter 7: idiopathic membranous nephropathy. Kidney Int Suppl. 2011;2(2):186–197.
   Google Scholar
• Beck LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457.
   PubMed Web of Science ®Google Scholar
• Yin P, Wang J, Liang W, et al. Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study. Ren Fail. 2020;42(1):675–683. doi: 10.1080/0886022X.2020.1792315.
   PubMed Web of Science ®Google Scholar
• Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol. 2015;26(2):302–313. doi: 10.1681/ASN.2014050502.
   PubMed Web of Science ®Google Scholar
• Rao SJ, Shen Q, Wang HM, et al. The association of anti-PLA2R with clinical manifestations and outcomes in idiopathic membranous nephropathy: a meta-analysis. Int Urol Nephrol. 2020;52(11):2123–2133. doi: 10.1007/s11255-020-02588-7.
   PubMed Web of Science ®Google Scholar
• Dong L, Li YQ, Guo SM, et al. Hypercholesterolemia correlates with glomerular phospholipase A2 receptor deposit and serum anti-phospholipase A2 receptor antibody and predicts proteinuria outcome in idiopathic membranous nephropathy. Front Immunol. 2022;13:905930. doi: 10.3389/fimmu.2022.905930.
   PubMed Web of Science ®Google Scholar
• Borza DB. Alternative pathway dysregulation and the conundrum of complement activation by IgG4 immune complexes in membranous nephropathy. Front Immunol. 2016;7:157. doi: 10.3389/fimmu.2016.00157.
   PubMed Web of Science ®Google Scholar
• Haddad G, Lorenzen JM, Ma H, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J Clin Invest. 2021;131(5):e140453.
   PubMed Web of Science ®Google Scholar
• Jullien P, Seitz Polski B, Maillard N, et al. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy. Clin Kidney J. 2017;10(2):209–214. doi: 10.1093/ckj/sfw121.
   PubMed Web of Science ®Google Scholar
• Rodas LM, Matas-Garcia A, Barros X, et al. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. Clin Kidney J. 2019;12(1):36–41. doi: 10.1093/ckj/sfy005.
   PubMed Web of Science ®Google Scholar
• Jurubita R, Obrisca B, Sorohan B, et al. Clinical phenotypes and predictors of remission in primary membranous nephropathy. J Clin Med. 2021;10(12):2624.
   PubMed Web of Science ®Google Scholar
• Guo W, Zhang Y, Gao C, et al. Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody. PeerJ. 2020;8:e8650. doi: 10.7717/peerj.8650.
   PubMed Web of Science ®Google Scholar
• Sun Y, Lan P, Feng J, et al. Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels. Ren Fail. 2022;44(1):731–740. doi: 10.1080/0886022X.2022.2068442.
   PubMed Web of Science ®Google Scholar
• Huh H, Lee H, Lee JP, et al. Factors affecting the long-term outcomes of idiopathic membranous nephropathy. BMC Nephrol. 2017;18(1):104. doi: 10.1186/s12882-017-0525-6.
   PubMedGoogle Scholar